Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Harald Hampel, Sid E. O’Bryant, José L. Molinuevo, Henrik Zetterberg, Colin L. Masters, Simone Lista, Steven J. Kiddle, Richard Batrla, Kaj Blennow

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine — most notably, oncology and cardiovascular diseases — allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.

Original languageEnglish
Pages (from-to)639-652
Number of pages14
JournalNature Reviews Neurology
Volume14
Issue number11
DOIs
StatePublished - 1 Nov 2018

Fingerprint

Alzheimer Disease
Biomarkers
Amyloidogenic Proteins
tau Proteins
Precision Medicine
Cerebrospinal Fluid
Cardiovascular Diseases
Medicine
Clinical Trials
Costs and Cost Analysis
Therapeutics
Research

Cite this

Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., ... Blennow, K. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639-652. https://doi.org/10.1038/s41582-018-0079-7
Hampel, Harald ; O’Bryant, Sid E. ; Molinuevo, José L. ; Zetterberg, Henrik ; Masters, Colin L. ; Lista, Simone ; Kiddle, Steven J. ; Batrla, Richard ; Blennow, Kaj. / Blood-based biomarkers for Alzheimer disease : mapping the road to the clinic. In: Nature Reviews Neurology. 2018 ; Vol. 14, No. 11. pp. 639-652.
@article{22221ab66db247cda0615409778c7a96,
title = "Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic",
abstract = "Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine — most notably, oncology and cardiovascular diseases — allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.",
author = "Harald Hampel and O’Bryant, {Sid E.} and Molinuevo, {Jos{\'e} L.} and Henrik Zetterberg and Masters, {Colin L.} and Simone Lista and Kiddle, {Steven J.} and Richard Batrla and Kaj Blennow",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41582-018-0079-7",
language = "English",
volume = "14",
pages = "639--652",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "11",

}

Hampel, H, O’Bryant, SE, Molinuevo, JL, Zetterberg, H, Masters, CL, Lista, S, Kiddle, SJ, Batrla, R & Blennow, K 2018, 'Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic', Nature Reviews Neurology, vol. 14, no. 11, pp. 639-652. https://doi.org/10.1038/s41582-018-0079-7

Blood-based biomarkers for Alzheimer disease : mapping the road to the clinic. / Hampel, Harald; O’Bryant, Sid E.; Molinuevo, José L.; Zetterberg, Henrik; Masters, Colin L.; Lista, Simone; Kiddle, Steven J.; Batrla, Richard; Blennow, Kaj.

In: Nature Reviews Neurology, Vol. 14, No. 11, 01.11.2018, p. 639-652.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Blood-based biomarkers for Alzheimer disease

T2 - mapping the road to the clinic

AU - Hampel, Harald

AU - O’Bryant, Sid E.

AU - Molinuevo, José L.

AU - Zetterberg, Henrik

AU - Masters, Colin L.

AU - Lista, Simone

AU - Kiddle, Steven J.

AU - Batrla, Richard

AU - Blennow, Kaj

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine — most notably, oncology and cardiovascular diseases — allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.

AB - Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine — most notably, oncology and cardiovascular diseases — allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85054570892&partnerID=8YFLogxK

U2 - 10.1038/s41582-018-0079-7

DO - 10.1038/s41582-018-0079-7

M3 - Review article

C2 - 30297701

AN - SCOPUS:85054570892

VL - 14

SP - 639

EP - 652

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 11

ER -